A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Dose Escalation Study to Evaluate the Safety and Pharmacokinetics/Pharmacodynamics of PF-06835375, a C-X-C Chemokine Receptor Type 5 Directed Antibody, in Patients with Systemic Lupus Erythematosus or Rheumatoid Arthritis

Researchers evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of PF‑06835375, a potent selective afucosyl immunoglobulin G1 antibody targeting C-X-C chemokine receptor type 5 that potentially depleted B cells, follicular T helper (Tfh) cells, and circulating Tfh-like cells, in patients with systemic lupus erythematosus and rheumatoid arthritis.